Pages that link to "Q420685"
Jump to navigation
Jump to search
The following pages link to rasagiline (Q420685):
Displaying 50 items.
- Parkinson's disease (Q11085) (← links)
- pethidine (Q55434) (← links)
- levodopa (Q300989) (← links)
- tramadol (Q407592) (← links)
- sertraline (Q407617) (← links)
- paroxetine (Q408471) (← links)
- fluvoxamine (Q409236) (← links)
- (RS)-citalopram (Q409672) (← links)
- frovatriptan (Q410195) (← links)
- linezolid (Q411377) (← links)
- sumatriptan (Q416978) (← links)
- fluoxetine (Q422244) (← links)
- bupropion (Q834280) (← links)
- vortioxetine (Q3563148) (← links)
- Monoamine oxidase B (Q21109462) (← links)
- From a Parkinson's disease expert: Rasagiline and the future of therapy (Q21202839) (← links)
- Rasagiline for levodopa-induced motor complications in Parkinson´s disease (Q24243502) (← links)
- Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy (Q24654614) (← links)
- N-Propargyl-1(S)-Aminoindan (Q27094763) (← links)
- Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline (Q28239657) (← links)
- Rasagiline: a review of its use in the management of Parkinson's disease (Q28239730) (← links)
- Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease (Q28262497) (← links)
- Livedo reticularis associated with rasagiline (azilect) (Q28267740) (← links)
- Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B (Q28346410) (← links)
- I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline (Q28485219) (← links)
- Azilect (Q29004877) (← links)
- Rasagiline Ratiopharm (Q29006398) (← links)
- Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data. (Q30640285) (← links)
- Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies (Q31060186) (← links)
- The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells (Q33183592) (← links)
- Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats (Q33615763) (← links)
- Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan (Q33821908) (← links)
- Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro (Q33825775) (← links)
- Multi criteria decision making to select the best method for the preparation of solid lipid nanoparticles of rasagiline mesylate using analytic hierarchy process (Q34039305) (← links)
- An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells (Q34132785) (← links)
- Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo (Q34269401) (← links)
- Rasagiline for the treatment of Parkinson's disease: an update (Q34493883) (← links)
- A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study (Q34555070) (← links)
- Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro (Q34581157) (← links)
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease (Q34612128) (← links)
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes (Q34628386) (← links)
- Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease. (Q34651186) (← links)
- Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease (Q34662060) (← links)
- Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. (Q34665690) (← links)
- Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy (Q34725080) (← links)
- Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs (Q34911093) (← links)
- Rasagiline: an anti-Parkinson drug with neuroprotective activity (Q35006961) (← links)
- Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. (Q35047710) (← links)
- Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia (Q35738987) (← links)
- Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition (Q35968602) (← links)